Exenterative pelvic surgery--eleven year experience of the Swansea Pelvic Oncology Group.
OBJECTIVE
To review indications for surgery and outcomes of patients with complex locally advanced pelvic malignancies treated by a multidisciplinary Pelvic Oncology Group.


METHODS
Between March 1992 and March 2003, 130 patients were jointly assessed in a monthly clinic involving urological, gynaecological, colorectal and plastic surgeons, an oncologist and nurse specialists. Seventy-six patients proceeded to exenterative surgery.


RESULTS
Rectal carcinoma and gynaecological cancers were the two most common indications for surgery. Median follow-up was 14 months (range 1-120 months). There were no deaths within 30 days of surgery. The morbidity rate was 28%. Predicted 5 years survival was 53% in cases with clear histological margins and no lymph node metastasis.


CONCLUSIONS
With careful patient selection and multi specialty care pelvic exenteration is a safe and effective option in the treatment of complex locally advanced pelvic malignancy.
Nguyen
D Q A
DQ
Swansea Pelvic Oncology Group, Singleton and Morriston Hospitals, Swansea, UK. daiqanguyen@hotmail.com
McGregor
A D
AD
Freites
O
O
Carr
N D
ND
Beynon
J
J
El-Sharkawi
A M M
AM
Lucas
M G
MG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010348:Patient Care Team; D018579:Patient Selection; D010385:Pelvic Exenteration / Q000401:mortality*; D010386:Pelvic Neoplasms / Q000401:mortality / Q000601:surgery*; D016019:Survival Analysis; D016896:Treatment Outcome